MEDICAL POLICY DETAILS

<table>
<thead>
<tr>
<th>Medical Policy Title</th>
<th>Tibial Nerve Stimulation (TNS) for Voiding Dysfunction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number</td>
<td>8.01.22</td>
</tr>
<tr>
<td>Category</td>
<td>Technology Assessment</td>
</tr>
<tr>
<td>Original Effective Date</td>
<td>03/17/11</td>
</tr>
<tr>
<td>Committee Approval Date</td>
<td>03/15/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 4/20/17, 04/19/18, 04/18/19, 06/18/20, 04/15/21, 04/21/22, 04/20/23</td>
</tr>
<tr>
<td>Current Effective Date</td>
<td>04/20/23</td>
</tr>
<tr>
<td>Archived Date</td>
<td>N/A</td>
</tr>
<tr>
<td>Archive Review Date</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Product Disclaimer

- If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
- If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.
- If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.
- If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.
- If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY STATEMENT

I. Based upon our criteria and assessment of the peer-reviewed literature, percutaneous posterior tibial nerve stimulation (PPTNS) has been medically proven to be effective and, therefore, is considered **medically appropriate** as a treatment modality for patients with urinary urge incontinence, nonobstructive urinary retention, or overactive bladder (OAB) symptoms who meet BOTH of the following criteria:

   A. Failure of conservative behavioral therapies of at least three months’ duration; and
   B. Failure of pharmacological therapy OR patient has a contraindication to pharmacological therapy. For urinary urge incontinence and OAB, that includes at least two anticholinergic or beta-3 adrenergic agonist medications and/or smooth muscle relaxants.

II. Based upon our criteria and assessment of the peer-reviewed literature, Tibial Nerve Stimulation (TNS) has not been medically proven to be effective and, therefore, is considered **investigational** for all other uses, including, but not limited to: voiding dysfunction due to a neurological condition, constipation, fecal incontinence, and chronic pelvic pain.

III. Based upon our criteria and assessment of the peer-reviewed literature, **implanted** TNS has not been medically proven to be effective and, therefore, is considered **investigational** for all indications.

Refer to Corporate Medical Policy #1.01.01 Transcutaneous and Percutaneous Nerve Stimulation as a Treatment for Pain and Other Conditions.

Refer to Corporate Medical Policy #1.01.19 Pelvic Floor Electrical Stimulation as a Treatment for Urinary or Fecal Incontinence.

Refer to Corporate Medical Policy #1.01.48 Neuromuscular Electrical Stimulation (NMES).

Refer to Corporate Medical Policy #7.01.10 Sacral Nerve Stimulation.

Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services.
POLICY GUIDELINE

Twelve weekly office visits for PPTNS treatment sessions are considered medically appropriate. Then, once monthly maintenance therapy will be considered, if the patient has exhibited at least a 50% improvement in voiding symptoms (based on documentation such as patient voiding diaries) after the initial 12 sessions. Maintenance therapy is also dependent on documentation of a continued treatment response.

DESCRIPTION

PPTNS is an office-based procedure that utilizes electrical neuromodulation in the treatment of voiding dysfunction in patients who have failed conservative therapies (e.g., behavioral, pharmacological). Voiding dysfunction includes urinary frequency, urgency, incontinence, and nonobstructive retention and is usually initially treated with behavioral interventions and/or medications such as anticholinergics. Behavioral therapies include (but are not are not limited to) fluid management, bladder training/timed voiding, and physiotherapy.

The procedure for PPTNS consists of the insertion of a needle above the medial malleolus into the posterior tibial nerve, followed by the application of low-voltage (10mA, 1–10 Hz frequency) electrical stimulation that produces sensory and motor responses (e.g., a tickling sensation and plantar flexion or fanning of all toes). The recommended course of treatment is an initial series of 12 weekly, office-based treatments, followed by an individualized maintenance treatment schedule.

While the posterior tibial nerve is located near the ankle, it is derived from the lumbar-sacral nerves (L4-S3), which control the bladder detrusor and perineal floor. Altering the function of the posterior tibial nerve with PPTNS is believed to improve voiding function and control.

PPTNS has also been proposed as treatment for individuals with non-neurogenic and neurogenic bladder syndromes and fecal incontinence.

Noninvasive PPTNS has also been delivered with surface electrodes (transcutaneous posterior tibial nerve stimulation or TPTNS). TPTNS is not addressed in this medical policy.

The eCoin Peripheral Neurostimulator (Valencia Technologies Corporation) is a coin-sized leadless stimulator that is implanted subcutaneously using local anesthetic in the lower leg and delivers 30-minute treatments without the need for users to manipulate to deliver stimulation. It received FDA approval on March 1, 2022. The device is indicated for the treatment of urgency urinary incontinence in individuals who are intolerant to or having an inadequate response to other more conservative treatments who have undergone a successful trial of PPTNS.

RATIONALE

In July 2005, the Urgent PC Neuromodulation System (Uroplasty, Inc.) received Section 510(k) marketing clearance from the FDA for PPTNS to treat patients suffering from urinary urgency, urinary frequency, and urge incontinence. In 2010, the cleared indication was changed to overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence. The Urgent PC Neuromodulation System is not FDA-cleared for other indications, such as the treatment of fecal incontinence.

Randomized, controlled trials (RCT) evaluating PPTNS for treating patients diagnosed with OAB syndrome have been published. In 2009, Peters and colleagues published an industry-sponsored, non-blinded comparison of PPTNS and extended-release tolterodine (Detrol LA) in women with OAB syndrome (the OrBIT trial). The study included 100 patients (50 per group). A total of 87 of the 100 patients (87%) completed the study, and voiding diary data were available for 84 patients, 41 of 50 (82%) in the PPTNS group and 43 of 50 (86%) in the tolterodine group. The primary outcome was the non-inferiority of PPTNS in the mean reduction in the number of voids per 24 hours after 12 weeks of treatment. Non-inferiority was defined as no more than a 20% difference in the mean void reduction. Study findings showed non-inferiority of PPTNS based on results for 84 patients. The study also reported a number of secondary outcomes, and findings on these were mixed. There were no statistically significant differences in the PPTNS and tolterodine groups for other symptoms recorded in the voiding diary, including mean change in episodes of nocturia, episodes of moderate to
severe urgency per day, and episodes of urge incontinence per day. In other secondary outcomes, 35 of 44 patients (79.5%) in the PPTNS group and 23 of 42 (54.8%) in the tolterodine group reported symptom improvement or cure. This difference was statistically significant (p=0.01), favoring the PPTNS group. However, the proportion of patients reporting symptom improvement (excluding the three patients reporting that they were cured) did not differ significantly between groups, 34 of 44 (77.3%) of those receiving PPTNS and 21 of 42 (50%) receiving tolterodine. Limitations of the OrBIT trial included the lack of blinding of patients and providers, and the lack of comparative data beyond the end of the initial 12-week treatment period.

Peters and colleagues published another industry-sponsored RCT in 2010 (SUMiT trial). The eligibility criteria included a score of at least four on the overactive bladder questionnaire (OAB-q) short form for urgency, self-reported bladder symptoms lasting at least three months, and failure of conservative care. A total of 220 patients were randomized, 110 to the PPTNS group and 110 to the sham group. Both groups received 12 weekly, 30-minute intervention sessions. The 12-week course of treatment was completed by 103 of 110 (94%) in the PPTNS group and 105 of 110 (95%) in the sham group. The primary study outcome was response to treatment based on a single-item global response assessment (GRA). The proportion of patients who responded to treatment based on the GRA (i.e., answered that symptoms were moderately or markedly improved) was 60 of 110 (54.5%) in the PPTNS group and 23 of 110 (20.9%) in the sham group; this difference was statistically significant, p<0.001. Intention-to-treat analysis was used for the primary endpoint only. Several secondary outcomes also favored the PPTNS group. The mean reduction in a symptom severity score (a lower score indicates less severity) was 36.7 in the PPTNS group and 29.2 in the sham group, p=0.01. Similarly, the mean reduction in a quality of life scale, the SF-36 (a higher score indicates higher quality of life), was 34.2 in the PPTNS group and 20.6 in the sham group, p=0.006. A limitation to this study was that the primary outcome, the GRA, was a single-item subjective measure. In addition, the SUMiT trial only reported comparative data immediately following the initial course of treatment; the study did not evaluate the long-term effectiveness of PPTNS. Unlike medication, which can be taken on an ongoing basis, PPTNS involves an initial 12-week course of treatment, followed by maintenance therapy, which, to date, has not been well-defined. Therefore, the assumption cannot be made that short-term treatment effects will be maintained.

In 2010, MacDiarmid and colleagues reported one-year follow-up data for patients from the OrBIT trial who had been assigned to the PPTNS group and had responded to the initial course of treatment, defined as reporting symptom improvement at 12 weeks. Thirty-three of the 35 responders were included. They received a mean of 12.1 (SD=4.9) treatments between the 12-week and 12-month visits, with a median of 17 days between treatments. Data were available for 32 of the 33 (97%) participants at six months and 25 of the 33 (76%) participants at 12 months. The mean reduction in number of voids per day from baseline (the original primary outcome of the study) was 3.2 (SD=3.7) at six months and 2.8 (SD=3.7) at 12 months. Other voiding diary outcomes at 12 months, based on 25 responses, were mean changes in nocturia episodes of -0.8, in episodes of moderate to severe urgency per day of -3.7, and in episodes of urge incontinence per day of -1.6. As noted above, this analysis was limited in that no data from the tolterodine group were available to compare long-term outcomes. Another limitation was that only PPTNS responders were included, rather than all of the patients assigned to PPTNS treatment.

The evidence for using PPTNS in individuals with fecal incontinence includes several RCTs and systematic reviews. The available RCTs have not found a clear benefit of PPTNS. Neither of the sham-controlled trials found that active stimulation was superior to sham for achieving the primary outcome, at least a 50% reduction in mean weekly fecal incontinence episodes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome. There are currently no PPTNS devices cleared by the FDA for the treatment of fecal incontinence.

**Implantable Peripheral Neurostimulators for the Treatment of Voiding Dysfunction:**

Approval for the eCoin Peripheral Neurostimulator was granted based on a prospective, open-label, multi-site, single arm clinical trial (NCT03556891) of 132 individuals. The primary outcome of the interventional study was the percentage of individuals experiencing 50% or better improvement in urgency urinary incontinence episodes after subcutaneous stimulation of the tibial nerve using the eCoin device, as measured by a 3-day voiding diary capturing the number of Urgency Incontinence Episodes/day, voids per/day, urgency episodes/day, nocturia episodes/day as well as quality of life (via Overactive Bladder Questionnaire). All individuals were successfully implanted with the device. Data was collected
at baseline and the primary outcome was assessed at 48 weeks after device activation. Device activation occurred 4 weeks after implantation. The analysis demonstrated 68% of the individuals were considered responders, experiencing a 50% or better improvement in their symptoms. Measured at 52 weeks post-implantation, 17/133 (12.78%) had experienced an adverse event, which mostly consisted of skin infection (3.01%) and issues with the device itself (14.7%) such as a stimulation issue, device dislocation, or device malfunction. The study was funded by the vendor, was unblinded, without a comparator group and limited length of follow-up. Studies with longer-term follow up and sound methodology are needed.

CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.
- CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

### CPT Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>64566</td>
<td>Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming</td>
</tr>
<tr>
<td>64590</td>
<td>Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling</td>
</tr>
<tr>
<td>0587T</td>
<td>Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve</td>
</tr>
<tr>
<td>0588T</td>
<td>Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve</td>
</tr>
<tr>
<td>0589T</td>
<td>Electronic analysis with simple programming of implanted integrated neurostimulation system (e.g., electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters</td>
</tr>
<tr>
<td>0590T</td>
<td>Electronic analysis with complex programming of implanted integrated neurostimulation system (e.g., electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters</td>
</tr>
</tbody>
</table>

### HCPCS Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No specific HCPCS codes</td>
</tr>
</tbody>
</table>

### ICD10 Codes

Medically Appropriate Codes:
Medical Policy: TIBIAL NERVE STIMULATION (TNS) FOR VOIDING DYSFUNCTION
Policy Number: 8.01.22
Page: 2 of 7

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>N32.81</td>
<td>Overactive bladder</td>
</tr>
<tr>
<td>N39.41</td>
<td>Urge incontinence</td>
</tr>
<tr>
<td>R35.0</td>
<td>Frequency of micturition</td>
</tr>
<tr>
<td>R35.81</td>
<td>Nocturnal polyuria</td>
</tr>
<tr>
<td>R35.89</td>
<td>Other polyuria</td>
</tr>
<tr>
<td>R39.15</td>
<td>Urgency of urination</td>
</tr>
</tbody>
</table>

REFERENCES


Key Article

KEY WORDS

Percutaneous/peripheral posterior tibial nerve stimulation, PTNS, SANS, Stoller afferent stimulation

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a Local Coverage Determination (LCD) for posterior tibial nerve stimulation. Please refer to the following LCD websites for Medicare Members: [https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33396&ver=10&CntrctrSelected=298*1&Cntrctr=298&name=National+Government+Services%2c+Inc.+(13201%2c+A+and+B+and+HHH+MAC%2c+J+-+K)&s=All&DocType=Active&bc=AggAAAQBAAM&]